ERBB2 and head and neck cancer: Early clinical studies and large-scale phase 3 trials showed improved outcome in patients with metastatic breast cancer and gastric cancer treated with trastuzumab (targeting HER2/neu) and patients with metastatic colorectal cancer and head and neck cancer treated with cetuximab (directed against EGFR) (167–170).